tbuckley/cabot-search huggingface dataset:
PARE0012 AWARENESS CAMPAING “LUPUS.GR 2020”
Authors: K. Antonopoulou, M. Konstantinidis
Journal: Annals of the Rheumatic Diseases (2020)

Background: LUPUS GR 2020 Objectives: To sensitize and educate the wide public about lupus To contribute to the process of de-stigmatization as the rigid problem of prejudice and stigma prevails. Methods: The campaign “LUPUS GR 2020” consists of photographs, each of which has a different message for Lupus and 2 TV spots. The well know artists participated did not take any fee. The campaign consists of Press Announcements in digital and off digital media, in Social Media (Instagram - Twitter - Facebook), in Eleana Site and in YouTube Post of the artists in their personal social media pages Press Conference Direct mail in international NGOs e.g. Lupus Europe, PAIN ALLIANCE EUROPE, AGORA PLATFORM, etc. Results: We announced the campaign on January 24, 2020. Until end of January, we have 36 press clipping, 3 TV interviews, more than 35.000 views of the post in our fb and increase of telephone calls in our help line about lupus Conclusion: The campaign has a high impact in the wide public as well as in all the stakeholders. Figure: Disclosure of Interests: None declared
Targeting anti-apoptotic bcl-2 family members with ABT-737 compliments the activity of bortezomib and conventional agents in in vitro models of lymphoproliferative malignancies
Authors: Luca Paoluzzi, Mithat Gonen, Jeffrey Gardner, Mark Heaney, Owen O'Connor
Journal: Cancer Research (2007)

4892  Over-expression of anti-apoptotic members of the Bcl-2 family have been observed in more that 80% of B-cell lymphomas and contribute to tumor initiation, progression and resistance to therapy. ABT-737 is a small molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-XL and Bcl-w. We investigated the cytotoxicity of ABT-737 alone or in combination with conventional and new agents in different lymphoma and myeloma cell lines (RL and SKI: diffuse large B-cell, HBL-2: mantle cell (MCL), H9: T-cell line, JJN-3: myeloma) and its effects on the mitochondrial membrane potential (Δψm) and apoptosis. For all cytotoxicity assays, luminescent cell viability was performed using CellTiter-GloTM followed by acquisition on a Fluoroskan Ascent FL fluorometer/luminometer. Cells were also stained with JC-1 dye with or without annexinV - APC then analyzed by flow-cytometry to assess the Δψm and apoptosis. For statistical analysis, multiple comparisons were handled using resampling within an analysis of variance model. All significance testing was done at the p   The IC50 ranged from 0.023 to 7.853 µM after a 48 hour exposure and from 0.025 to 6.71 µM after a 72 hour exposure. Specifically, the IC50 after 48 and 72 hours respectively was as follows: RL - 0.239 µM and 0.283 µM; SKI - 0.164 µM and 0.097 µM; HBL-2 - 0.023 µM and 0.025 µM; JJN3 - 7.182 µM and 4.796 µM; H9 - 7.853 µM and 6.71 µM.  We also combined ABT-737 at 0.1 µM for up to 72h with 0.01 uM rituximab (R), etoposide (E), bortezomib (B), doxorubicin (D), 4-hydroxycyclophosphamide (H), or pralatrexate (PDX) given for a 24h period starting from time zero, or after 24h or 48h from the beginning. Multiple comparison analysis revealed that ABT+B was significantly superior to every group except PDX alone after 24h (p=0.0891), and to every group after 48h. After normalization of each group to the correspondent control, the time dependent effects of ABT-737 were exemplified by the superior cytotoxicity of ABT-737 administered 24 hours or less prior to exposure to bortezomib. Preliminary studies to assess the effects of ABT-737 on the Δψm in the RL and HBL-2 cell lines showed that incubation for 24h with ABT-737 from 0.001 μM to 10 μM was associated with concentration dependent depolarization. The MCL line showed more sensitivity compared to the large B-cell line in accordance with the cytotoxicity data: the exposure to ABT at 0.05 μM was associated with a decrease of less than 10% for RL against more than 80% for HBL-2. When ABT-737 was combined with B for up to 48h, we also observed an increase in apoptosis associated with depolarization. These data suggest that targeting Bcl-2 family members with both conventional cytotoxic agents and bortezomib may help chemosensitize lymphoma to conventional therapies, especially MCL. In vivo experiments are now underway.
Covid-19: It’s too soon to lift lockdown
Authors: Fiona Godlee
Journal: BMJ (2020)

Let’s start with some good news. The pandemic is waning in many parts of the world, and health systems are showing how they can innovate and adapt. While we count the terrible toll of covid-19 (doi:10.1136/bmj.m1835) and continue asking hard questions of our governments (doi:10.1136/bmj.m2052), clinicians and patients are embracing new ways of doing things: virtual wards are helping to keep covid patients out of hospital (doi:10.1136/bmj.m2119), mental health services are experimenting with phone triage and virtual appointments (doi:10.1136/bmj.m2106), and doctors are supporting each other through their uniquely shared covid experience (doi:10.1136/bmj.m1499). And in other news the NHS has launched a race and health observatory, after The BMJ ’s call for action to end racial …
AB1061 2019 ACR/EULAR CLASSIFICATION CRITERIA FOR IGG4-RELATED DISEASE IN RUSSIAN COHORT OF PATIENTS.
Authors: E. Sokol, S. Palshina, A. Torgashina, J. Khvan
Journal: Annals of the Rheumatic Diseases (2020)

Background: IgG4-related disease (IgG4-RD) is a systemic immunomediated fibroinflammatory condition that can affect almost any organ in the body. This is the reason for dramatic variety of clinical symptoms and complexity of diagnostics. 2011 Comprehensive diagnostic criteria (CDC) for IgG4-RD are used to establish the diagnosis for all lesions (except autoimmune pancreatitis type 1). In 2019 the new ACR/EULAR classification criteria for IgG4-RD were proposed to facilitate the formation of more homogenous groups of patients primarily for clinical trials inclusion purpose. They also provide a framework for clinicians considering diagnosis of IgG4-RD. Objectives: To evaluate 2019 ACR/EULAR classification criteria for IgG4-RD in Russian cohort of patients with IgG4-RD. Methods: 59 patient with IgG4-RD according to CDC with biopsy proven diagnosis were included. Results: The mean number of affected organs was 2.1; 31 patients (52,5%) were women. Majority of patients had sialoadenitis (25 patients) and/or orbital disease (31 patients), 9 had retroperitoneal fibrosis (RPF). Other affected organs were lungs, pancreas, lymph nodes, paranasal sinuses, thyroid and low urinary tract. Twenty five (25) patients (42,4%) had definite, 14 (23,3%) probable and 20 (34,3%) possible diagnosis of IgG4-RD. Twenty three (23) patients (39%) didn’t fulfill the 2019 ACR/EULAR classification criteria for IgG4-RD. Among them were the majority of patients with RPF (7 patients) who were lacking other organ involvement and IgG4 hypersecretion either in the tissue or serum. The majority of excluded cases were due to inadequate pathomorphological evaluation (lacking of the exact number and percentage (if &gt;40%) of IgG4+ cells), lacking of multi-organ involvement or different patterns of involvement, e.g. in case of lungs involvement. Conclusion: The new 2019ACR/EULAR classification criteria for IgG4-RD are very useful in evaluation of typical organ involvement and systemic course of IgG4-RD. It is essential to adjust Russian pathomorphologists’s approach to cell counting and percentage determination for IgG4-RD cases to get suitable protocols. Disclosure of Interests: None declared
AB0208 ASSOCIATION OF RHEUMATOID FACTOR, HLA-DRB1 SHARED EPITOPE (SE) AND SMOKING WITH RADIOGRAPHIC OUTCOME IN RHEUMATOID ARTHRITIS
Authors: E. Mole, A. Tarassi, A. Tzioufas, M. N. Manoussakis, A. Tsirogianni, T. Athanassiades, V. Kitsiou, S. Gazi, P. Vlachoyiannopoulos
Journal: Annals of the Rheumatic Diseases (2020)

Background: Genetic and environmental factors interact in aetiopathogenesis of Rheumatoid Arthritis (RA). However, it remains unclear whether current smoking, presence of Rheumatoid factor (RF) and HLA-DRB1 SE influence the radiographic outcome. Objectives: To clarify the possible associations between radiographic outcome, HLA-DRB1 SE, RF and smoking status in patients with longstanding RA. Methods: An observational study of 240 consecutive Greek patients with RA, whose mean age and mean disease duration was 65.31±12.5 and 12.7±11.8 years respectively. Among them 74.17% were female, 40% were smokers, 60.42% had positive RF and 68.33% possessed at least one SE allele. HLA-DRB1 alleles were typed by molecular techniques (PCR-SSOP and SSP). X-rays of hands and feet were performed and scored by the Sharp-van der Hejde score (SHS) method. Results: Results were stratified by RF and smoking status and analyzed by multivariate logistic regression. Overall, the mean SHS was significantly higher in RF positive than RF negative patients and in smokers than non-smokers (52.76±31.1 vs 38.4±31.96, p: 0.0007, 55.33±38.56 vs 26.8±22.32, p &lt;0.0001, respectively). Furthermore, patients that possessed at least one SE allele had higher SHS than SE negative (35.49±24.76 vs 25.74±19.22, p: 0.0013). An association between radiographic severity and SE was found in RF positive patients. More specifically, seropositive patients carrying at least one SE allele had higher SHS than those lacking SE (40.85±33.21 vs 29.23±24.72, p: 0.037). On the other hand, smokers with at least one SE allele had higher SHS when compared to smokers without SE (29.27±25.20 vs 20±17.22, p: 0.048). Among RF negative and non-smokers RA patients, no significant association was found between the presence of HLA-DRB1 SE and radiographic severity. Conclusion: Our data indicate that in longstanding RA there is an association between RF positivity, the presence of SE, current smoking status and radiographic outcome. Disclosure of Interests: None declared
Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study
Authors: Benoit Painvin, Pauline Guillot, Marie-Clémence Verdier, Arnaud Gacouin, Adel Maamar
Journal: Intensive Care Medicine (2020)

Dear Editor,The benefit of hydroxychloroquine (HCQ) in the treatment of coronavirus disease (COVID-19) is still under investigation, and randomized control trials worldwide are currently recruiting patients.Data on HCQ pharmacokinetics (PK) exist in lupus patients but are scarce in COVID-19 critically ill patients [1][2][3].In our intensive care unit (ICU), patients were started on a 10-day oral course of HCQ 200 mg t.i.d, or 200 mg b.i.d if they had acute kidney injury (AKI) defined as creatinine clearance < 50 ml/min [4].Oral loading dose was 400 mg, or 200 mg if patients had AKI.We targeted trough blood concentrations between 1 and 2 mg/L [4, 5].HCQ can induce critical side effects such as prolonged QT on electrocardiogram (EKG), severe arrhythmias, and hypoglycemia.This toxicity combined with lack of experience using HCQ led us to measure daily blood trough and peak concentrations over a 12-day period to evaluate PK parameters.Samples were also collected around first hemodialysis (HD) session and in dialysis bath.We included eight patients with normal renal function, five patients with AKI of whom four required renal replacement therapy and one patient with veno-venous extracorporeal life support (ECLS) (eFig.2).Median age was 58 (interquartile range 53-70) years, seven (50%) male, and Sequential Organ Failure Assessment (SOFA) score at admission was 5 (3-7).At day one of treatment, all patients were mechanically ventilated.Median
Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients
Authors: François Dépret, Alexa Hollinger, Alain Cariou, Nicolas Deye, Antoine Vieillard-Baron, Marie-Céline Fournier, Samir Jaber, Charles Damoisel, Qin Lu, Xavier Monnet, Isabelle Rennuit, Michael Darmon, Marc Leone, Bertrand Guidet, Romain Sonneville, Philippe Montravers, Sébastien Pili-Floury, Jean-Yves Lefrant, Jacques Duranteau, Pierre-François Laterre, Nicolas Brechot, Haikel Oueslati, Bernard Cholley, Joachim Struck, Oliver Hartmann, Alexandre Mebazaa, Etienne Gayat, Matthieu Legrand
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Subclinical acute kidney injury (sub-AKI) refers to patients with low serum creatinine but elevated alternative biomarkers of AKI. Its incidence and outcome in critically ill patients remain, however, largely unknown. Plasma proenkephalin A 119-159 (penKid) has been proposed as a sensitive biomarker of glomerular function.Objectives: In this ancillary study of two cohorts, we explored the incidence and outcome of sub-AKI based on penKid.Methods: A prospective observational study in ICUs was conducted. FROG-ICU (French and European Outcome Registry in ICUs) enrolled 2,087 critically ill patients, and AdrenOSS-1 (Adrenomedullin and Outcome in Severe Sepsis and Septic Shock-1) enrolled 583 septic patients. The primary endpoint was 28-day mortality after ICU admission. Sub-AKI was defined by an admission penKid concentration above the normal range (i.e., >80 pmol/L) in patients not meeting the definition of AKI. A sensitivity analysis was performed among patients with estimated glomerular filtration rate above 60 ml/min/1.73 m2 at ICU admission.Measurements and Main Results: In total, 6.1% (122/2,004) and 6.7% (39/583) of patients from the FROG-ICU and AdrenOSS-1 cohorts met the definition of sub-AKI (11.6% and 17.5% of patients without AKI). In patients without AKI or with high estimated glomerular filtration rate, penKid was associated with higher mortality (adjusted standardized hazard ratio [HR], 1.4 [95% confidence interval, 1.1-1.8]; P = 0.010; and HR, 1.6 [95% confidence interval, 1.3-1.8]; P < 0.0001, respectively) after adjustment for age, sex, comorbidities, diagnosis, creatinine, diuresis, and study. Patients with sub-AKI had higher mortality compared with no AKI (HR, 2.4 [95% confidence interval, 1.5-3.7] in FROG-ICU and 2.5 [95% confidence interval, 1.1-5.9] in AdrenOSS-1).Conclusions: Sub-AKI defined using penKid occurred in 11.6-17.5% of patients without AKI and was associated with a risk of death close to patients with AKI.
Mortality Among Persons with Both Asthma and Chronic Obstructive Pulmonary Disease Aged ≥25 Years, by Industry and Occupation — United States, 1999–2016
Authors: Katelynn E. Dodd, John Wood, Jacek M. Mazurek
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Patients with asthma typically have chronic airway inflammation, variable airflow limitation, and intermittent respiratory symptoms; patients with chronic obstructive pulmonary disease (COPD) often have fixed airflow limitation and persistent respiratory symptoms.Some patients exhibit features suggesting that they have both conditions, which is termed asthma-COPD overlap.These patients have been reported to have worse health outcomes than do those with asthma or COPD alone (1).To describe mortality among persons aged ≥25 years with asthma-COPD overlap, CDC analyzed 1999-2016 National Vital Statistics multiple-cause-of-death mortality data* extracted from the National Occupational Mortality System (NOMS), which included industry and occupation † information collected from 26 states § for the years 1999, 2003, 2004, and 2007-2014.Age-adjusted death rates per one million persons ¶ and proportionate mortality ratios (PMRs)** were calculated.During 1999-2016, 6,738 male decedents (age-adjusted rate per million = 4.30) and 12,028 female decedents (5.59) had both asthma and COPD assigned on their death certificate as the underlying or contributing cause of death.The annual age-adjusted death rate per million among decedents with asthma-COPD overlap declined from * https://www.cdc.gov/nchs/data_access/Vitalstatsonline.htm.† Guidelines for reporting industry and occupation on death certificates instruct recorders to report decedent's "kind of business/industry" and "usual occupation" (i.e., "the type of job the individual was engaged in for most of his or her working life").§ Colorado, Florida,
The patient as person: an update
Authors: Dawn P Richards
Journal: British Journal of Sports Medicine (2020)

I live with a chronic, incurable disease called rheumatoid arthritis (RA). According to my healthcare system, this makes me a patient. But I can tell you I consider myself a lot of other things before I introduce myself to anyone as a patient or as a person who lives with RA. In fact those words (patient, person living with RA) are the ones I choose only when I’m in the healthcare system or when I’m part of some type of project that includes a patient perspective. Those words make me feel less empowered, less influential and less skilled than the others at the table in those situations. I am quite certain that when I’m in professional situations where I offer myself up as a patient, I am looked at ‘differently’—and not in a ‘good way’ of differently.

I contend that most patients don’t identify themselves as a patient first and foremost–this is a label imposed on us by our healthcare systems. Sarah Riggare is a person who lives with Parkinson’s disease and who uses a stunning visual and explanation to convey how little time she spends with her neurologist annually: ‘I visit my neurologist twice a year, for about 30 min. That is one hour per year. The rest of the year’s 8765 hours, I spend in self-care’.1 This is similar to the time I spend annually with my …
Cost effectiveness analysis of strategies for child health in developing countries
Authors: Tessa Tan-Torres Edejer, Moses Aikins, Robert Black, Lara Wolfson, Raymond Hutubessy, David B Evans
Journal: BMJ (2005)

To determine the costs and effectiveness of selected child health interventions-namely, case management of pneumonia, oral rehydration therapy, supplementation or fortification of staple foods with vitamin A or zinc, provision of supplementary food with counselling on nutrition, and immunisation against measles.Cost effectiveness analysis.Efficacy data came from published systematic reviews and before and after evaluations of programmes. For resource inputs, quantities came from literature and expert opinion, and prices from the World Health Organization Choosing Interventions that are Cost Effective (WHO-CHOICE) database,Cost effectiveness ratios clustered in three groups, with fortification with zinc or vitamin A as the most cost effective intervention, and provision of supplementary food and counselling on nutrition as the least cost effective. Between these were oral rehydration therapy, case management of pneumonia, vitamin A or zinc supplementation, and measles immunisation.On the grounds of cost effectiveness, micronutrients and measles immunisation should be provided routinely to all children, in addition to oral rehydration therapy and case management of pneumonia for those who are sick. The challenge of malnutrition is not well addressed by existing interventions.
AB1316-HPR COMORBIDITIES IMPACT ON PHYSICAL REHABILITATION PROGRAM OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS
Authors: V. Salaru, A. Vizdoaga, L. Mazur-Nicorici, M. Cebanu, T. Rotaru, S. Vetrila, M. Garabajiu, N. Loghin-Oprea, V. Sadovici-Bobeica, M. Mazur
Journal: Annals of the Rheumatic Diseases (2020)

Background: Physical rehabilitation is proposed as a method of non-pharmacological treatment of knee osteoarthritis (OA) by the EULAR and OARSI recommendations. At the same time, presence of concomitant diseases could influence the condition of patients and the outcomes of the rehabilitation program. Objectives: To evaluate the frequency of comorbidities in OA patients and to appreciate their impact on outcomes of the physical rehabilitation program. Methods: A prospective control case study was conducted in the University Rehabilitation Center. The patients underwent clinical examination, VAS scale was used to assess level of pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) with 5 domains (Pain, Symptoms, ADL, Sport, QoL) for joint function assessment. These parameters were evaluated at the onset of the program (T0) and at the end of the 10th day (T1). Medical data records, general clinical exam and Charlson Comorbidities Index (CCI) assessed the comorbidities. Results: 48 patients with OA were included in the study, 37 patients of them were found with comorbidities. The most frequent associated diseases were: cardiovascular- 76.6%, obesity-59.9%, and endocrine - 12.9% cases. At T0, significantly lower levels in the group with comorbidities were identified on the domains Pain, Sport and QoL. The CCI in patients with comorbidities was 3.29 ± 0.14 points (82.1% for 1-year survival rate). At the T1 moment, we found an improvement in joint functionality in both groups. The mean value of the VAS score group of patients without comorbidities decreased from 48,18 mm to 21,36 mm (p &lt;0.05) and for the group of patients with comorbidities – 64,2 at / 36,2 mm (p&lt;0.001). Significant improvement in joint function in the comorbidities group was in Pain (p &lt;0.01), Sport (p &lt;0.05) and Qol (p &lt;0.01) domains, at the same in patients without comorbidities, the improvement was significant in all 5 domains. Conclusion: Comorbidities are highly associated to knee osteoarthritis and prove to have a negative influence on the results of the physical rehabilitation program; therefore, we would recommend to apply individualized rehabilitation programs adapted to the associated conditions of each patient. Disclosure of Interests: None declared
Agrin Promotes Coordinated Therapeutic Processes Leading to Improved Cardiac Repair in Pigs
Authors: Andrea Baehr, Kfir Baruch Umansky, Elad Bassat, Victoria Jurisch, Katharina Klett, Tarik Bozoglu, Nadja Hornaschewitz, Olga Solyanik, David Kain, Bartolo Ferraro, Renee Cohen-Rabi, Markus Krane, Clemens Cyran, Oliver Soehnlein, Karl Ludwig Laugwitz, Rabea Hinkel, Christian Kupatt, Eldad Tzahor
Journal: Circulation (2020)

Background: Ischemic heart diseases are leading causes of death and reduced life quality worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), a large number of patients with MI develop chronic heart failure over time. We previously reported that a fragment of the extracellular matrix protein agrin promotes cardiac regeneration after MI in adult mice. Methods: To test the therapeutic potential of agrin in a preclinical porcine model, we performed ischemia–reperfusion injuries using balloon occlusion for 60 minutes followed by a 3-, 7-, or 28-day reperfusion period. Results: We demonstrated that local (antegrade) delivery of recombinant human agrin to the infarcted pig heart can target the affected regions in an efficient and clinically relevant manner. A single dose of recombinant human agrin improved heart function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments along with complementary murine studies revealed myocardial protection, improved angiogenesis, inflammatory suppression, and cell cycle reentry as agrin’s mechanisms of action. Conclusions: A single dose of agrin is capable of reducing ischemia–reperfusion injury and improving heart function, demonstrating that agrin could serve as a therapy for patients with acute MI and potentially heart failure.
Respiratory Syncytial Virus hospitalization burden: a nation-wide population-based analysis, 2000-2017
Authors: Aharona Glatman-Freedman, Zalman Kaufman, Yael Applbaum, Rita Dichtiar, Ada Steiman, Ethel-Sherry Gordon, Lital Keinan-Boker, Tamy Shohat, Ziona Haklai
Journal: Journal of Infection (2020)
CTCF is dispensable for immune cell transdifferentiation but facilitates an acute inflammatory response
Authors: Grégoire Stik, Enrique Vidal, Mercedes Barrero, Sergi Cuartero, Maria Vila-Casadesús, Julen Mendieta-Esteban, Tian V. Tian, Jinmi Choi, Clara Berenguer, Amaya Abad, Beatrice Borsari, François le Dily, Patrick Cramer, Marc A. Marti-Renom, Ralph Stadhouders, Thomas Graf
Journal: Nature Genetics (2020)